BRPI0610968A2 - composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical - Google Patents

composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical

Info

Publication number
BRPI0610968A2
BRPI0610968A2 BRPI0610968-3A BRPI0610968A BRPI0610968A2 BR PI0610968 A2 BRPI0610968 A2 BR PI0610968A2 BR PI0610968 A BRPI0610968 A BR PI0610968A BR PI0610968 A2 BRPI0610968 A2 BR PI0610968A2
Authority
BR
Brazil
Prior art keywords
blood composition
ucb
hemoatopoietic
treating
methods
Prior art date
Application number
BRPI0610968-3A
Other languages
English (en)
Inventor
Chow Robert
Original Assignee
Stemcyte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37482333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0610968(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stemcyte, Inc. filed Critical Stemcyte, Inc.
Publication of BRPI0610968A2 publication Critical patent/BRPI0610968A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dentistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Environmental Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue de cordão umbilical as composições de sangue de cordão umbilical (ucb) da presente invenção compreendem as características únicas de apresentarem plasma que é substancialmente depletado da unidade de ucb e células sanguíneas vermelhas (rbc) que não são depletadas da unidade de ucb. referidas unidades de ucb podem ser preparadas por meio de um processo que combina depleção de plasma com crioconservação, seleção, descongelamento, e/ou transplante de células-tronco hematopoiéticas proporcionando resultado clínico superior mediante a maximização da recuperação de células após o processamento e dose de células de infusão após o descongelamento. proporciona-se também métodos para tratamento de uma ampla variedade de doenças malignas e de doenças benignas associadas com o sistema hemoatopoiético mediante administração de composições de ucb da presente invenção.
BRPI0610968-3A 2005-06-02 2006-06-02 composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical BRPI0610968A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68712705P 2005-06-02 2005-06-02
US60/687127 2005-06-02
US73395605P 2005-11-03 2005-11-03
US60/733956 2005-11-03
PCT/US2006/021405 WO2006130812A2 (en) 2005-06-02 2006-06-02 Plasma-depleted, non-red blood cell-depleted cord blood compositions and methods of use

Publications (1)

Publication Number Publication Date
BRPI0610968A2 true BRPI0610968A2 (pt) 2019-05-14

Family

ID=37482333

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610968-3A BRPI0610968A2 (pt) 2005-06-02 2006-06-02 composição de sangue de cordão umbilical, e, métodos para tratar uma doença maligna ou distúrbio benigno associado com o sistema hemoatopoiético e para preparar uma composição de sangue umbilical

Country Status (11)

Country Link
EP (1) EP1906729B1 (pt)
JP (1) JP2008545755A (pt)
KR (1) KR20080027295A (pt)
AT (1) ATE551062T1 (pt)
AU (1) AU2006252363A1 (pt)
BR (1) BRPI0610968A2 (pt)
CA (1) CA2609266A1 (pt)
IL (1) IL187641A0 (pt)
MX (1) MX2007015201A (pt)
RU (1) RU2007148802A (pt)
WO (1) WO2006130812A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121120A1 (en) * 2007-03-28 2008-10-09 Thermogenesis Corp. Stem and progenitor cell compositions recovered from bone marrow or cord blood; system and method for preparation thereof
RU2343928C1 (ru) * 2007-04-03 2009-01-20 Открытое акционерное общество "Институт стволовых клеток человека" Способ получения ядросодержащих клеток из пуповинной крови
KR101708067B1 (ko) * 2008-09-03 2017-02-17 메소블라스트, 아이엔씨. 혈액 형성 전구 세포의 증식
WO2011127472A1 (en) * 2010-04-09 2011-10-13 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function
JP6165627B2 (ja) * 2010-04-09 2017-07-19 フレッド ハッチンソン キャンサー リサーチ センター Ｈｌａの適合なしに造血機能を提供するための組成物および方法
HK1197262A1 (en) * 2011-02-18 2015-01-09 永生细胞公司 Stem cells packaging and shipping
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
JP6531256B2 (ja) 2014-11-14 2019-06-19 日本赤十字社 臍帯血および末梢血の凍結保存方法および凍結保存用溶液
RU2590688C2 (ru) * 2014-11-19 2016-07-10 Публичное акционерное общество "Институт Стволовых Клеток Человека" Способ получения суспензии ядросодержащих клеток из пуповинной крови со стандартизированной концентрацией
KR101850780B1 (ko) * 2015-03-06 2018-04-23 아주대학교산학협력단 암 치료용 세포 치료제 및 이의 병용 요법
EP4017507A4 (en) * 2019-08-20 2023-09-06 Stemcyte, Inc. TREATMENT OF CARDIOVASCULAR DISEASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789147A (en) * 1994-12-05 1998-08-04 New York Blood Center, Inc. Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood
US20030215942A1 (en) * 2002-02-14 2003-11-20 Stemcyte, Inc. Undesignated allogeneic stem cell bank

Also Published As

Publication number Publication date
IL187641A0 (en) 2008-03-20
EP1906729A2 (en) 2008-04-09
ATE551062T1 (de) 2012-04-15
CA2609266A1 (en) 2006-12-07
RU2007148802A (ru) 2009-07-20
WO2006130812A3 (en) 2007-09-13
AU2006252363A1 (en) 2006-12-07
EP1906729A4 (en) 2009-08-12
MX2007015201A (es) 2008-03-14
EP1906729B1 (en) 2012-03-28
HK1124484A1 (en) 2009-07-17
WO2006130812A2 (en) 2006-12-07
JP2008545755A (ja) 2008-12-18
KR20080027295A (ko) 2008-03-26

Similar Documents

Publication Publication Date Title
IL187641A0 (en) Umbilical cord blood compositions
Wang et al. The therapeutic potential of umbilical cord mesenchymal stem cells in mice premature ovarian failure
Shrestha et al. Enhanced healing of diabetic wounds by subcutaneous administration of human umbilical cord derived stem cells and their conditioned media
Showel et al. Advances in treating acute myeloid leukemia
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
Oliansky et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review
AR015926A1 (es) Celulas modificadas geneticamente y su utilizacion en la profilaxis o terapia de enfermedades
WO2004104166A3 (en) Administration of hyaluronic acid to enhance the function of transplanted stem cells
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
Yun et al. Reactive oxygen species induce MMP 12‐dependent degradation of collagen 5 and fibronectin to promote the motility of human umbilical cord‐derived mesenchymal stem cells
WO2006060709A3 (en) Biological pathways in progenitor cells
BR112018072701A2 (pt) métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais
Schepici et al. Mesenchymal stromal cells preconditioning: a new strategy to improve neuroprotective properties
Wang et al. Administration of the Resveratrol Analogues Isorhapontigenin and Heyneanol‐A Protects Mice Hematopoietic Cells against Irradiation Injuries
Rudnitsky et al. Mesenchymal stem cells and their derivatives as potential longevity-promoting tools
NZ603442A (en) Treatment of proliferative diseases
Cao et al. Therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome: potential mechanisms and challenges
DE60334382D1 (de) Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
WO2018053618A1 (en) Methods of culturing mesenchymal stromal cells
BRPI0515428A (pt) terapia por injeção ao tumor de células dendrìticas (dcti)
Vargas-Torres et al. Towards chlorocytes for therapeutic intravascular photosynthesis
BRPI0707247A8 (pt) vacina para tumor compreendendo células tumorais alogênicas ou xenogênicas
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
Monzen et al. Heavy ion beam irradiation regulates the mRNA expression in megakaryocytopoiesis from human hematopoietic stem/progenitor cells
ATE527342T1 (de) Zellkultur mit nm23, nm23 umfassende zellkulturmedien sowie therapeutische verwendung von in gegenwart von nm23 kultivierten zellen

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO 020070170526/RJ DE 30/11/2007.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.7 NA RPI NO 2080 DE 16/11/2010 POR TER SIDO INDEVIDA.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.6.1 NA RPI NO 2135 DE 06/12/2011 POR TER SIDO INDEVIDA.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]